Obesity Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight

DelveInsight’s Obesity Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES, June 13, 2024 /EINPresswire.com/ -- DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s Obesity Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast

Some of the key facts of the Obesity Market Report:
The Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the United States held the largest market share for obesity, exceeding USD 2,000 million. This surpassed the market sizes of obesity in comparison to the European Union Four (EU4) countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
By the year 2034, it is expected that WEGOVY (Semaglutide) and ZEPBOUND (Tirzepatide) will attain significant market dominance across the seven major markets.
In December 2023, Pfizer has released initial findings from the Phase IIb clinical trial (NCT04707313) evaluating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF06882961), in adults diagnosed with obesity but not type 2 diabetes. The trial successfully achieved its primary objective by showing a statistically significant reduction in body weight compared to baseline measurements.
In June 2023, The extensive results from the SURMOUNT-2 trial, a phase 3 clinical study evaluating the efficacy and safety of Eli Lilly and Company's tirzepatide at doses of 10 mg and 15 mg for weight management in individuals with obesity or overweight and type 2 diabetes, demonstrated that tirzepatide led to more significant weight loss compared to the placebo at both dosage levels. These findings were presented at a symposium during the American Diabetes Association's^® (ADA) 83rd Scientific Sessions and simultaneously published in The Lancet.
In recent times, there has been an increasing emphasis on the creation of innovative treatments for obesity, which encompass drug combinations like SAXENDA (Liraglutide), XENICAL (Orlistat), WEGOVY (Semaglutide), QYSMIA (Phentermine-Topiramate), among others.
DelveInsight's estimates suggest that approximately 60% of the total prevalent cases of obesity among adults in the 7 major markets (7MM) were accounted for by the United States in 2023.
Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others
The Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.

Obesity Overview
Obesity is a medical condition characterized by an excessive accumulation of body fat to the extent that it may have adverse effects on health. It is typically assessed using the body mass index (BMI), which is calculated by dividing a person's weight in kilograms by the square of their height in meters (kg/m²).

Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Obesity Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obesity Epidemiology Segmentation:
The Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Obesity
Prevalent Cases of Obesity by severity
Gender-specific Prevalence of Obesity
Diagnosed Cases of Episodic and Chronic Obesity

Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast

Obesity Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies
IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
ZEPBOUND (tirzepatide): Eli Lilly and Company
Survodutide (BI 456906): Boehringer Ingelhium
DD03: D&D Pharmatech
AX-0601: ProQR Therapeutics
NPM 139: Nano Precision Medical
BK-1701: Bukwang Pharmaceutical
CBW-520: Caliway Biopharmaceutics
YH34160: Yuhan
TERN-601: Terns Pharmaceuticals
Thermostem: BioRestorative Therapies
SCO-267: SCOHIA PHARMA
CT-181: Click Therapeutics
HM15136: Hanmi Pharmaceuticals
NNC0480-0389: Novo Nordisk
EMP-16: Empros Pharma
CT-868: Carmot Therapeutics
Tirzepatide: Eli Lilly and Company
SemaglutideOral: Novo Nordisk

Obesity Market Drivers
Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.

Obesity Market Barriers
However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

Scope of the Obesity Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others
Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Obesity Unmet Needs, KOL’s views, Analyst’s views, Obesity Market Access and Reimbursement

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment

Table of Contents
1. Obesity Market Report Introduction
2. Executive Summary for Obesity
3. SWOT analysis of Obesity
4. Obesity Patient Share (%) Overview at a Glance
5. Obesity Market Overview at a Glance
6. Obesity Disease Background and Overview
7. Obesity Epidemiology and Patient Population
8. Country-Specific Patient Population of Obesity
9. Obesity Current Treatment and Medical Practices
10. Obesity Unmet Needs
11. Obesity Emerging Therapies
12. Obesity Market Outlook
13. Country-Wise Obesity Market Analysis (2020–2034)
14. Obesity Market Access and Reimbursement of Therapies
15. Obesity Market Drivers
16. Obesity Market Barriers
17. Obesity Appendix
18. Obesity Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here